P/E ratio for OPKO Health (OPK)
P/E ratio as of September 2023 (TTM): -6.00
According to OPKO Health 's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -6. At the end of 2021 the company had a P/E ratio of -96.2.
P/E ratio history for OPKO Health from 2001 to 2022
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2021 | -96.2 | -221.77% |
| 2020 | 79.0 | -2948.3% |
| 2019 | -2.77 | -75.12% |
| 2018 | -11.1 | 25.13% |
| 2017 | -8.91 | -96.17% |
| 2016 | -233 | 101.42% |
| 2015 | -115 | 362.19% |
| 2014 | -25.0 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Johnson & Johnson JNJ | 32.3 | -638.02% | 🇺🇸 USA |
 Abbott Laboratories ABT | 29.8 | -596.51% | 🇺🇸 USA |
 Regeneron Pharmaceuticals REGN | 20.5 | -442.06% | 🇺🇸 USA |
 Bristol-Myers Squibb BMY | 15.6 | -359.70% | 🇺🇸 USA |
 LabCorp LH | 22.0 | -467.26% | 🇺🇸 USA |
 Alnylam Pharmaceuticals
ALNY | -19.9 | 232.08% | 🇺🇸 USA |
 Teva Pharmaceutical Industries TEVA | -5.18 | -13.75% | 🇮🇱 Israel |
 Ardelyx ARDX | -13.6 | 127.01% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.